Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?

Pharmacopsychiatry

Volumn 31, Issue 2, 1998, Pages 60-67

  Diebold, K ^a,d   Michel, G ^b   Schweizer, J ^a   Diebold Dorsam M ^c   Fiehn, W ^a   Kohl, B ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ABBOTT GMBH AND CO KG   (Germany)

^c Central Hospital for Psychiatry   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMITRIPTYLINOXIDE; BENPERIDOL; BROMPERIDOL; BUTYROPHENONE DERIVATIVE; CHOLESTEROL; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DIBENZEPIN; DOXEPIN; FLUOXETINE; FLUPENTIXOL; FLUVOXAMINE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; LEVOMEPROMAZINE; LITHIUM CARBONATE; LOW DENSITY LIPOPROTEIN; MAPROTILINE; PERAZINE; PIPAMPERONE; PROTHIPENDYL; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRIACYLGLYCEROL; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DEPRESSION; DRUG MIXTURE; DRUG RESPONSE; FEMALE; HOSTILITY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MANIC DEPRESSIVE PSYCHOSIS; MENTAL PATIENT; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; RATING SCALE; REMISSION; SCHIZOIDISM; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031921690     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979300     Document Type: Article

References (56)

1. Baumann, U., R.-D. Stieglitz: Testmanual zum AMDP-System. Ernpirische Studien zur Psychopathologie. Hrsg.: Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie AMDP. Springer, Berlin, Heidelberg, New York, Tokyo, 1983
2. Benkert, O., H. Hippius: Psychiatrische Pharmakotherapie. 6. korr. Aufl., Springer, Berlin, Heidelberg, New York 1996
3. Block, E. R., D. Edwards: Effect of plasma membrane fluidity on serotonin transport by endothelial cells. Am. J. Physiol. 253 (1987) 672-678
4. Branconnier, R. J., J. O. Cole, G. F. Oxenkrug, S. Ghazvinian, E. C. Dessain, K. F. Spera, J. M. Kane, K. Cole, S. Sarantakos, D. Dunner, D. Avery: Cardiovascular effects of imipramine and bupropion in aged depressed patients. Psychopharmacol. Bull. 19 (1983) 658-662
5. Burckardt, D., E. Raeder, V. Müller, P. Imhof, H. Neubauer: Cardiovascular effects of tricyclic and tetracyclic antidepressants. JAMA, 239 (1978) 213-216
6. Clark, M. L., G. A. Braun, R. Hewson, E. A. Serafetinides, J. P. Colmore, D. K. Rahhal: Trifluperidol and cholesterol in man. Clin. Pharmacol. Therap. 9 (1968) 333-340
7. Clark, M. L., P. C. Johnson: Amenorrhea and elevated level of serum cholesterol produced by a trifluoro-methylated phenothiazine (SKF 5354-A). J. Clin. Endocrinol. Metabol. 20 (1960) 641-646
8. Clark, M. L., T. S. Ray, A. Paredes, R. E. Ragland, J. P. Costiloe, C. W. Smith, S. Wolf: Chlorpromazine in women with chronic schizophrenia: The effect on cholesterol levels and cholesterol-behavior relationships. Psychosomatic Medicine XXIX (1967) 634-642
9. Diebold, K., E. Freisburger, D. Barwich: Untersuchung chemischer, zellulärer und hormoneller Parameter des Blutes bei affektpsychotischen Patienten unter Lithiumprophylaxe. Arzneim.-Forsch./Drug Res. 32 (1982) 884
10. Dingley, A. J., M. F. Veale, N. J. King, G. F. King: Two-dimensional 1 H NMR studies of membrane changes during the activation of primary T lymphocytes. Immunomethods 4 (1994) 127-138
11. Duits, N., F. M. Bos: Depressive symptoms and cholesterol-lowering drugs. Lancet 341 (1993) 114
12. Dursun, S. M., J. G. Burke, M. A. Reveley: Low serum cholesterol and depression. BMJ 309 (1994) 273-274
13. Engelberg, H.: Low serum cholesterol and suicide. Lancet 339 (1992) 727-729
14. Fowkes, F. G. R., G. C. Leng, P. J. Donnan, I. J. Deary, R. A. Riemersma, E. Housley: Serum cholesterol, triglycerides, and aggression in the general population. Lancet 340 (1992) 995-998
15. Gebhardt, R., A. Pietzcker, A. Strauss, M. Stoeckel, C. Langer, K. Freudenthal: Skalenbildung im AMDP-System. Arch. Psychiatr. Nervenkr. 233 (1983) 223-245
16. Glueck, C. J., F. E. Kuller, T. Hamer, R. Rodriguez, F. Sosa, L. Sieve-Smith, J. A. Morrison: Hypocholesterolemia, hypertriglyceridemia, suicide, and suicide ideation in children hospitalized for psychiatric diseases. Pediatric Research 35 (1994) 602-610
17. Glueck, C. J., M. Tieger, E. Kunkel, T. Tracy, J. Speirs, P. Streicher, E. Illig: Improvement in symptoms of depression and in an index of life Stressors accompany treatment of severe hypertriglyceridemia. Biol. Psychiatry 34 (1993) 240-252
18. Golier, J. A., P. M. Marzuk, A. C. Leon, C. Weiner, K. Tardiff: Low serum cholesterol level and attempted suicide. Am. J. Psychiatry 152 (1995) 419-423
19. Hatch, F. T., P. K. Reissel, T. M. W. Poon-King: A study of coronary heart disease in young men: characteristics and metabolic studies of patients and comparison with agematched healthy controls. Circulation 33 (1966) 679-703
20. Hawton, K., P. Cowen, D. Owens, A. Bond, M. Elliott: Low serum cholesterol and suicide. Brit. J. Psychiat. 162 (1993) 818-825
21. Henkin, Y., A. Jackson, A. Oberman: Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice. JAMA 2, 267, 7 (1992) 961-968
22. Heron, D. S., M. Hershkowitz, M. Shinitzky, D. Samuel: In: Ertlaner, U. Z., Y. Duai, W. Silman, V. I. Teichberg, Z. Vogel (eds.): Neurotransmitters and their Receptors. New York, John Wiley & Sons, 1980
23. Hirata, F., J. Axelrod: Phospholipid methylation and biological signal transmission. Science 209 (1980) 1082-1090
24. Jenkins, C. D., C. G. Hames, S. J. Zyzanski: Psychological traits and serum lipids. I. Findings from the California psychological inventory. Psychosom. Med. 31 (1969) 115-128
25. Karabanow, O.: Double-Blind controlled study in phobias and obsessions. J. Int. Med. Res. 5 (1977) 42-48
26. Kohlmeier, M.: Simple method for preparing and quantifying very-low-density lipoprotein. Clin. Chem. 30 (1984) 295-297
27. Lechleitner, M., F. Hoppichler, G. Konwalinka, J. R. Patsch, H. Braunsteiner: Depressive symptoms in hypercholesterolaemic patients treated with paravastatin. Lancet 340 (1992) 910
28. Le-Quang-Sang, K. H., M. Mazeaud, C. Astarie, V. Duranthon, F. Driss, M. A. Devynck: Plasma lipids and platelet membrane fluidity in essential hypertension. Thromb. Haemost. 69 (1993) (1) 70-76
29. Lindberg, G., L. Rastam, B. Gullberg, G. A. Eklund: Low serum cholesterol concentration and short term mortality from injuries in men and women. BMJ 305 (1992) 277-279
30. Magni, G., M. Garreau, B. Orofamma, R. Palminteri: Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: An overview of six double-blind studies versus tricyclics. Neuropsychobiology 20 (1988) 126-131
31. Martinez, J. A., J. J. Velasco, M. D. Urbistondo: Effects of pharmacological therapy on anthropometric and biochemical status of male and female institutionalized psychiatric patients. J. Am. College of Nutrition 13 (1994) 192-197
32. Mefferd, R. B., E. H. Labrosse, A. M. Gawienowski, R. J. Williams: Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. J. Nerv. Ment. Dis. 127 (1958) 167-179
33. Morgan, R. E., L. A. Palinkas, E. L. Barrett-Connor, D. L. Wingard: Plasma cholesterol and depressive symptoms in older men. Lancet 341 (1993) 75-79
34. Muldoon, M. F., S. B. Manuck, K. A. Matthews: Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 301 (1990) 309-314
35. Muzulu-S. I., R. F. Bing, R. I. Norman: Human erythrocyte membrane fluidity and calcium pump activity in primary combined hyperlipidaemia. Clin. Sci. Colch. 88 (3) (1995) 307-310
36. Othmer, E., S. C. Othmer, W. C. Stern, J. van Wyck Fleet: Long-term efficacy and safety of bupropion. J. Clin. Psychiat. 44 (1983) 153-156
37. Palinkas, L. W., E. Barrett-Connor, R. E. Morgan, D. L. Wingard: Serum lipids and depression. Lancet 341 (1993) 563
38. Rodes, J. F., J. Berreur-Bonnenfant, A. Tremolieres, S. C. Brown: Modulation of membrane fluidity and lipidic metabolism in transformed rat fibroblasts induced by the sesquisterpenic hormone farnesylacetone. Cytometry 19 (1995) 217-225
39. Royer, R. J.: Toxicité hépatique des antidépresseurs. Thérapie 36 (1981) 299-304
40. SAS Institute Inc.: SAS/STAT User's Guide. Release 6.03. NC: SAS Institute Inc., 1988
41. Sasaki, J., M. Funakoshi, K. Arakawa: Lipids and apolipoproteins in patients treated with major tranquilizers. Clin. Pharmacol. Ther. 37 (1985) 684-687
42. Sasaki, J., G. Kumagae, T. Sata, M. Kuramitsu, K. Arakawa: Decreased concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines. Atherosclerosis 51 (1984) 163-169
43. Serafetinides, E. A., J. P. Colmore, D. K. Rahhal, M. L. Clark: Trifluperidol in chronic male psychiatric patients. Behavioural Neuropsychiat 3 (1971) 10-12
44. Shafique, M., I. A. Khan, M. H. Akhtar, I. Hussain: Serum lipids and lipoproteins in schizophrenic patients receiving major tranquilizers. JPMA 10 (1988) 260-261
45. Simpson, G. M., T. B. Cooper, G. A. Braun: Further studies on the effect of butyrophenones on cholesterol synthesis in humans. Curr. Ther. Res. 9 (1967) 413-418
46. Simpson, G. M., T. B. Cooper: The effect of three butyrophenones on serum cholesterol levels. Curr. Ther. Res. 8 (1966) 249-255
47. Sletten, I. W., J. A. Nilsen, R. C. Young, J. T. Anderson: Blood lipids and behavior in mental-hospital patients. Psychosom. Med. 26, (1964) 261-266
48. Strandberg, T. E., J. Valvanne, R. S. Tilvis: Serum lipids and depression. Lancet 341 (1993) 433-434
49. Taylor, C. B., Ch. Hayward, R. King, A. Ehlers, J. Margraf, R. Maddock, D. Clark, W. T. Roth, W. S. Agras: J. Clin. Psychopharm. 10 (1990) 112-118
50. Tieger, M., F. Kunkel, T. Tracy, J. Speirs, P. Stereicher, E. Illig, J. Vandegrift, C. J. Glueck: Amelioration of depression by treatment of severe hypertriglyceridemia. Clin. Res. 39 (1991) 464 A
51. Vachon, A., M. Evreux, P. Jean-Louis: Étude contrôlée à double insu de l'amineptine et de la maprotiline dans le traitement des dépressions masquées en gastro-entérologie (phase III). Psychol. Méd. 18 (1986) 1285-1298
52. Vendsborg, P. B., S. Prytz: Glucose tolerance and serum lipids in man after long-term lithium administration. Acta psychiat. scand. 53 (1976) 64-69
53. Virkkunen, M.: Serum cholesterol in antisocial personality. Neuropsychobiology 5 (1979) 27-30
54. Virkkunen, M.: Serum cholesterol levels in homicidal offenders. Neuropsychobiology 10 (1983) 65-69
55. Virkkunen, M., H. Penttinen: Serum cholesterol in aggressive conduct disorder: a preliminary study. Biol. Psychiatry 19 (1984) 435-439
56. Yeragani, V. K., R. Balon, R. Pohl, C. Ramesh: Imipramine treatment and increased serum cholesterol levels. Canad. J. Psychiat. 34 (1989) 845